The Successful Treatment of Gatifloxacin-resistant Staphylococcus aureus Keratitis With Zymar® (Gatifloxacin 0.3%) in a NZW Rabbit Model

We demonstrated the “Proof of Principle” that in vitro antibiotic resistance, based on CLSI standards, does not always correlate with in vivo treatment failure in the eye. An aggressive treatment regimen with Zymar® appears to overcome in vitro resistance, resulting in the successful treatment of Gat-R-Sa infections in the NZW rabbit keratitis model.